Etzer Darout
Stock Analyst at Barclays
(4.66)
# 252
Out of 5,182 analysts
175
Total ratings
55.56%
Success rate
33.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Overweight | $17 → $21 | $16.76 | +25.30% | 1 | Apr 8, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Overweight | $50 → $78 | $68.92 | +13.17% | 3 | Apr 7, 2026 | |
| TVRD Tvardi Therapeutics | Maintains: Equal-Weight | $5 → $4 | $3.39 | +17.99% | 2 | Apr 1, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Equal-Weight | $56 → $53 | $52.65 | +0.66% | 12 | Mar 30, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $142 → $148 | $120.16 | +23.17% | 2 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $113 → $119 | $105.98 | +12.29% | 7 | Mar 19, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $16 | $4.82 | +231.95% | 15 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Outperform | $143 → $128 | $102.92 | +24.37% | 5 | Mar 11, 2026 | |
| MGNX MacroGenics | Maintains: Overweight | $3 → $4 | $3.46 | +15.61% | 11 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $50 → $70 | $49.96 | +40.11% | 10 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $78 → $79 | $67.51 | +17.02% | 5 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $2.92 | +139.73% | 7 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $224 | $203.42 | +10.12% | 1 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $13.06 | +106.74% | 9 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $10.75 | +179.07% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $3.86 | +184.97% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $117 | $97.82 | +19.61% | 3 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $41 → $44 | $44.89 | -1.98% | 6 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $119 → $133 | $87.71 | +51.64% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $16.74 | +67.26% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $15.82 | +83.31% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $34.55 | -30.54% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $11.00 | +63.64% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $25.15 | -28.43% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $24.23 | +44.45% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $9.68 | +189.26% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $56.22 | +122.34% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $5.67 | +129.28% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $5.85 | -48.72% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $17.51 | +99.89% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.02 | +6,076.47% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.78 | +1,416.85% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $107.61 | +24.52% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $28.55 | +68.13% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $151.97 | -21.04% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.39 | +331.65% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $204.80 | -59.96% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.29 | +259.17% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $309.66 | -45.10% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $97.95 | -61.20% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $4.25 | +1,123.53% | 1 | Mar 28, 2018 |
Relay Therapeutics
Apr 8, 2026
Maintains: Overweight
Price Target: $17 → $21
Current: $16.76
Upside: +25.30%
Oruka Therapeutics
Apr 7, 2026
Maintains: Overweight
Price Target: $50 → $78
Current: $68.92
Upside: +13.17%
Tvardi Therapeutics
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $3.39
Upside: +17.99%
Terns Pharmaceuticals
Mar 30, 2026
Downgrades: Equal-Weight
Price Target: $56 → $53
Current: $52.65
Upside: +0.66%
ABIVAX Société Anonyme
Mar 24, 2026
Maintains: Overweight
Price Target: $142 → $148
Current: $120.16
Upside: +23.17%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $113 → $119
Current: $105.98
Upside: +12.29%
CytomX Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $10 → $16
Current: $4.82
Upside: +231.95%
BioNTech SE
Mar 11, 2026
Maintains: Outperform
Price Target: $143 → $128
Current: $102.92
Upside: +24.37%
MacroGenics
Mar 10, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $3.46
Upside: +15.61%
Scholar Rock Holding
Mar 4, 2026
Maintains: Outperform
Price Target: $50 → $70
Current: $49.96
Upside: +40.11%
Mar 4, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $67.51
Upside: +17.02%
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.92
Upside: +139.73%
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $203.42
Upside: +10.12%
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $13.06
Upside: +106.74%
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $10.75
Upside: +179.07%
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.86
Upside: +184.97%
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $97.82
Upside: +19.61%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $44.89
Upside: -1.98%
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $87.71
Upside: +51.64%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $16.74
Upside: +67.26%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $15.82
Upside: +83.31%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $34.55
Upside: -30.54%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $11.00
Upside: +63.64%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $25.15
Upside: -28.43%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $24.23
Upside: +44.45%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $9.68
Upside: +189.26%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $56.22
Upside: +122.34%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.67
Upside: +129.28%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $5.85
Upside: -48.72%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $17.51
Upside: +99.89%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.02
Upside: +6,076.47%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.78
Upside: +1,416.85%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $107.61
Upside: +24.52%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $28.55
Upside: +68.13%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $151.97
Upside: -21.04%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.39
Upside: +331.65%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $204.80
Upside: -59.96%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.29
Upside: +259.17%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $309.66
Upside: -45.10%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $97.95
Upside: -61.20%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $4.25
Upside: +1,123.53%